STEAP2 and prostate cancer: These data reveal that human-murine cross-reactive STEAP2 CAR-Ts can effectively elicit antitumor activity without toxicity in in vivo models of prostate cancer, including subcutaneous cell line xenografts, orthotopic models of bone metastases, and patient-derived xenograft models.